The aim of personalized medicine is to provide the customized treatment likely to work best for each individual. A narrow interpretation of the definition attributes the appropriate treatment to be based on the patientās molecular phenotype. A broader interpretation includes cell-based therapies that are derived from a patientās own cells, or cells from a related or tissue-matched donor. Basic research findings contributing to the knowledge of the molecular and cellular basis of immune-mediated control of cancer and infectious diseases have created opportunities to develop new forms of cell-based vaccination for cancer and chronic infections like HIV. Cell therapy laboratories have developed from their roots in bone marrow transplantation and blood banking into what can now be described as cellular engineering laboratories where cells can be isolated, enriched, transduced, activated, expanded and otherwise manipulated in ways to change or enhance the function of in vivo-derived cells for eventual reinfusionā¦
Tag: <span>autologous T-cells</span>
Xcyte Therapies has recently introduced a bioreactor-based process for the GMP manufacture of autologous activated T cells, Xcellerated T Cellsā¢, for clinical trials. Using a single customized disposable 20-L Cellbagā¢ with a working volume of 10 L on a customized Wave Bioreactor platform (Wave Biotech, Bridgewater, NJ), the Xcellerateā¢ III Process has supplanted the 60-L static Xcellerate II Process that used 60 bags cultured in a standard incubator. Compared to the Xcellerate IIā¢ Process, the Xcellerate III Process significantly reduces the overall labor, the number of culture containers, bag spikes, and sterile connections required, as well as reducing the process volume and the cost of goods, while more than quadrupling the final cell density and doubling the facility capacity. These process improvements are achieved without compromising final product composition or quality…
We have developed a procedure for large-scale enrichment, growth and harvesting of T cells suitable for adoptive immunotherapy. In two recently completed clinical trials, we investigated the feasibility of immune reconstitution in patients with HIV infection, or with relapsed/refractory Non-Hodgkin’s Lymphoma (NHL) following infusions of autologous activated CD4+ T cells or CD4+/CD8+ T cells. Autologous T cells were activated via CD3/CD28 stimulation, ex vivo, and were then reinfused…